Nurix Therapeutics Faces 85.8% Upside with $30.18 Mean Price Target
Nurix Therapeutics shares have risen 4% over the past four weeks to close at $16.24, with a $30.18 mean analyst price target implying an 85.8% upside and estimates ranging from $23 to $41. Analysts have raised three EPS forecasts this month, lifting the consensus by 3.1%.
1. Recent Price Performance and Targets
Nurix Therapeutics closed the latest session at $16.24, marking a 4% gain over the past month. The current mean price target of $30.18 suggests an 85.8% potential upside from the latest closing price.
2. Analyst Price Target Distribution
Seventeen analysts set short-term targets ranging from $23 to $41, resulting in a standard deviation of $4.39. The tighter clustering around the mean indicates strong analyst agreement on the stock’s upside potential.
3. EPS Estimate Revisions
Over the past 30 days, three EPS estimates were revised higher and none were cut, raising the consensus estimate by 3.1%. Nurix Therapeutics holds a Zacks Rank #2 (Buy), placing it in the top 20% of rated stocks.
4. Caution on Price Targets
Empirical studies show that price targets can be overly optimistic due to analysts’ business incentives. Investors are advised to treat these targets skeptically and use them as a starting point for deeper fundamental research.